Search results

SAN DIEGO, January 3, 2022 – Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and…

Dr. Falk Pharma Australia is pleased to announce the 2022 Dr. Falk Pharma-GESA research grant has been awarded to

SAN DIEGO and FREIBURG, Germany, Aug. 13, 2020 /PRNewswire/ — Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to the discovery, development, and commercialization of…

Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal (“GI”) disorders, announced today that it has…

Dr. Falk Pharma GmbH and Zedira announce start of the phase 2b clinical trial of ZED1227, a direct-acting and specific inhibitor of tissue transglutaminase, in patients with Celiac Disease.

Dr. Falk Pharma would like to thank all responders to our survey on Adults with EoE.

Dr. Falk Pharma Australia is pleased to announce we have received TGA regulatory approval for Jorveza^® 0.5mg orally disintegrating budesonide tablet - indicated "for the treatment of…